Secondary Adjuvant Long Term Study With Arimidex

PHASE3CompletedINTERVENTIONAL
Enrollment

3,484

Participants

Timeline

Start Date

March 1, 2004

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Breast Cancer
Interventions
DRUG

Anastrozole

1mg tablet daily

Trial Locations (60)

1021

Research Site, Vienna

1050

Research Site, Vienna

1070

Research Site, Vienna

1090

Research Site, Vienna

1130

Research Site, Vienna

1140

Research Site, Vienna

1160

Research Site, Vienna

1180

Research Site, Vienna

1210

Research Site, Vienna

1220

Research Site, Vienna

2130

Research Site, Mistelbach

2340

Research Site, Mödling

2410

Research Site, Hainburg an der Donau

2500

Research Site, Baden

2620

Research Site, Neunkirchen

2700

Research Site, Wiener Neustadt

3100

Research Site, Sankt Pölten

3270

Research Site, Scheibbs

3300

Research Site, Amstetten

3500

Research Site, Krems

3830

Research Site, Waidhofen an der Thaya

4010

Research Site, Linz

4021

Research Site, Linz

4240

Research Site, Freistadt

4400

Research Site, Steyr

4560

Research Site, Kirchdorf

4600

Research Site, Wels

4810

Research Site, Gmunden

4820

Research Site, Bad Ischl

4840

Research Site, Vöcklabruck

4910

Research Site, Ried im Innkreis

5020

Research Site, Salzburg

5620

Research Site, Schwarzach

6020

Research Site, Innsbruck

6060

Research Site, Hall in Tirol

6330

Research Site, Kufstein

6511

Research Site, Zams

6807

Research Site, Feldkirch

6853

Research Site, Dornbirn

6900

Research Site, Bregenz

7000

Research Site, Eisenstadt

7350

Research Site, Oberpullendorf

7400

Research Site, Oberwart

7540

Research Site, Güssing

8020

Research Site, Klagenfurt

8036

Research Site, Graz

8160

Research Site, Weiz

8280

Research Site, Fürstenfeld

8330

Research Site, Feldbach

8700

Research Site, Leoben

8786

Research Site, Rottenmann

8970

Research Site, Schladming

9020

Research Site, Klagenfurt

9026

Research Site, Klagenfurt

9300

Research Site, Sankt Veit an der Glan

9400

Research Site, Wolfsberg

9500

Research Site, Villach

9504

Research Site, Villach

9900

Research Site, Lienz

A-1090

Research Site, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00295620 - Secondary Adjuvant Long Term Study With Arimidex | Biotech Hunter | Biotech Hunter